NCT06518005View on ClinicalTrials.gov

Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2030

Conditions
Crigler-Najjar Syndrome
Interventions
DRUG

Imlifidase

Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion

DRUG

GNT0003

GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion

Trial Locations (1)

92141

RECRUITING

Hopital Antoine BECLERE, Clamart

Sponsors

Lead Sponsor

Genethon

Collaborators (1)

Hansa Biopharma AB
All Listed Sponsors
collaborator

Hansa Biopharma AB

INDUSTRY

lead

Genethon

OTHER

NCT06518005 - Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome | Biotech Hunter | Biotech Hunter